News|Articles|September 27, 2023

Thread Introduces New Electronic Clinical Outcome Assessment Suite

Platform includes an expanded global library.

Thread Research revealed in a company press release that it has officially launched a suite of new complex electronic clinical outcome assessment (eCOA) features, including an expanded global library, to its decentralized research platform serving global researchers. Reportedly, the new features enable the platform to process complex eCOA data collection while presenting only relevant data to the site teams and participants.

Thread stated that with these new features, clients can now:

Eliminate 100% of custom development activities for eCOA and related study quality risks.
Reduce eCOA implementation costs by up to 54% leveraging Thread's no-code platform.
Decrease data capture clicks by up to 90% for participants to increase patient retention.
Launch studies with complex eCOA in nine weeks or less.
Increase compliance consistently above 94% by eliminating unnecessary technology burden.

"The launch of these enhanced eCOA features provides our clients with the next-generation functionality needed to increase speed, scale consistently, and reduce study risks," said John Reites, co-founder, CEO, Thread, in the aforementioned release. "These features bring us closer to bringing research to everyone, everywhere with our innovative approach to Patient-First eCOA."

Reference: THREAD LAUNCHES SUITE OF NEW FEATURES AND EXPANDED LIBRARY TO MODERNIZE ECOA SOLUTIONS. PR Newswire. September 26, 2023. Accessed September 27, 2023. https://www.prnewswire.com/news-releases/thread-launches-suite-of-new-features-and-expanded-library-to-modernize-ecoa-solutions-301938170.html

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

November 6th, 2026

What FDA Inspections Reveal About the Quality of APAC Clinical Trial Sites

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how FDA inspection findings at APAC sites compare with those in the US and Europe, and why the common issues, such as informed consent versioning, are not unique to the region.

November 6th, 2026

ACT Brief: Asia Pacific Site Perceptions, Community Access Gap, and VeonGen Gene Therapy Alignment

In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design.

Ten key risk indicators can flag recurring good clinical practice problems in noncompliance, safety, data quality, and oversight, but only when normalization, trial timing, and combined signals are taken into account. Credit: Stock.Adobe.com/Andrey Popov.

November 6th, 2026

The 10 Most Powerful Study KRIs in RBQM and GCP Issues They Can Prevent

Risk-based quality management depends on knowing what to monitor and on interpreting what the signals mean.

November 5th, 2026

Why Outdated Perceptions of APAC Clinical Trial Sites Persist Among Smaller Biotechs

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how regulatory reform and inspection data contradict the view that APAC sites are slower or lower quality, and why sponsors need to update their assumptions.

November 5th, 2026

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health

In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.

November 5th, 2026

ACT Brief: Capturing Trial Friction, AI Matching Model Comparisons, and Boehringer’s Oncology Deal

In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.

November 4th, 2026

Comparing OpenAI and Mistral on Clinical Trial Matching

Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.

November 4th, 2026

The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time

In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.